Following the election, significant spikes in searches for moving out of America suggest heightened interest in international relocation. moveBuddha identifies the states with the highest interest in top international destinations and each state’s top move-to country.
Read More
Denmark-based Aim Robotics partners with BlueBay Automation to establish Aim Robotics US, bringing innovative dispensing solutions for collaborative robots closer to North American manufacturers.
Read More
Rising demand for hybrid propulsion systems in military drones extends to adjacent vehicle markets adopting intelligent power management and compact generators. Rugged, compact, and powerful Hercules hybrid-ready propulsion solutions satisfy the need for extended range and mission agility for any uncrewed applications.
Read More
Should professionals use bulky recording devices or opt for a compact, wearable solution? The Intelligent Voice Badge offers seamless documentation with cutting-edge AI technology.
Read MoreThe combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million
Jaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial for its cancer supportive care drug crofelemer; results in breast cancer patients accepted for poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS)
Jaguar initiated commercial launch in October 2024 for Gelclair®, the company's third prescription product, in alignment with Jaguar's focus on cancer supportive care
Jaguar is initiating two Phase 2 trials in Q4, 2024 and supporting multiple investigator-initiated proof-of-concept studies ("IIT") of crofelemer for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU, and Middle East/North Africa (MENA) regions; results of IITs expected by the end of 2024 and throughout 2025
REMINDER: Jaguar to host investor webcast Wednesday, November 13th at 8:30 a.m. Eastern regarding Q3 2024 financials and company updates; Click here to register for webcast
Read More
Company is creating its own wine. Capitalizing on the projected $2.1 billion U.S. CBD-infused beverage market by 2025, CBDL positions itself at the forefront of innovation, unlocking immense revenue potential in the booming CBD alcohol sector.
Read More
Recent Study Indicates Favorable Rare Earth Elements Mix at Lemhi Pass - Abundant Concentrations of Magnet and Heavy REEs Relative to Many Current and Proposed REE Mines Globally
Read MoreThird Quarter 2024 Highlights:
Completes reverse acquisition merger transaction with Scott's Liquid Gold-Inc.
Revenues of $15.4 million for the third quarter of 2024, an increase of 20.6%
Revenues of $42.4 million for the nine months ended September 30, 2024, an increase of 7.6%
Unearned performance revenue of $23.3 million as of September 30, 2024
Assets under management (AUM) grew to $8.3 billion as of September 30, 2024
Board of Directors declares a $0.053 per share dividend